Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMicrotech Med-B
Stock Code02235
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於糖尿病管理,提供糖尿病治療及糖尿病監測醫療器械(包括貼敷式胰島素泵系統、持續血糖監測系統及血糖監測系統等),以在中國和全球範圍內優化糖尿病的管理方式。
Listing Date2021-10-19
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國浙江省杭州市余杭區倉前街道留澤街108號
Business Address (Hong Kong)中國香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitemicrotechmd.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 30.50 / shares
Offer Price RangeFinal offer price only, no range
Lot Size100 shares
Entry ThresholdHK$ 3,050
Par ValueRMB 1.0 / shares
Offer Period2021-10-06 to 2021-10-11
Global Offering Shares63,529,500 shares
HK Public Offer Shares (Initial)6,353,000 shares (10.0%)
Public Offer Lots (Initial)63,530lots (Pool A31,765lots,Pool B31,765lots)
International Placing Shares (Initial)57,176,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO423,529,500 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share61.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,937,649,750

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 100 HK$ 3,050
2 lots 200 HK$ 6,100
3 lots 300 HK$ 9,150
4 lots 400 HK$ 12,200
5 lots 500 HK$ 15,250
6 lots 600 HK$ 18,300
7 lots 700 HK$ 21,350
8 lots 800 HK$ 24,400
9 lots 900 HK$ 27,450
10 lots 1,000 HK$ 30,500
15 lots 1,500 HK$ 45,750
20 lots 2,000 HK$ 61,000
25 lots 2,500 HK$ 76,250
30 lots 3,000 HK$ 91,500
35 lots 3,500 HK$ 106,750
40 lots 4,000 HK$ 122,000
45 lots 4,500 HK$ 137,250
50 lots 5,000 HK$ 152,500
60 lots 6,000 HK$ 183,000
70 lots 7,000 HK$ 213,500
80 lots 8,000 HK$ 244,000
90 lots 9,000 HK$ 274,500
100 lots 10,000 HK$ 305,000
200 lots 20,000 HK$ 610,000
300 lots 30,000 HK$ 915,000
400 lots 40,000 HK$ 1,220,000
500 lots 50,000 HK$ 1,525,000
600 lots 60,000 HK$ 1,830,000
700 lots 70,000 HK$ 2,135,000
800 lots 80,000 HK$ 2,440,000
1,000 lots 100,000 HK$ 3,050,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 200,000 HK$ 6,100,000
3,000 lots 300,000 HK$ 9,150,000
5,000 lots 500,000 HK$ 15,250,000
6,000 lots 600,000 HK$ 18,300,000
7,000 lots 700,000 HK$ 21,350,000
20,000 lots 2,000,000 HK$ 61,000,000
31,765 lots 3,176,500 HK$ 96,883,250

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.17B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +705%

Valuation & Financials

Market Cap (at Offer Price)HK$ 12,917,649,750
H-Share Market Cap (at Offer Price)HK$ 1,937,649,750
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣121.25百萬元
Period-End Cash Balance人民幣549.8百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 51,86375,277
Cost of sales -27,780-38,733
Gross profit 24,08336,544
Other income and gains, net 8,71627,663
Selling and distribution expenses -27,003-55,059
Administrative expenses -33,615-45,758
Operating profit -78,303-120,942
Net finance costs -311-308
Profit before tax -78,614-121,250
Income tax expense 00
Profit for the year -78,614-121,250
Profit attributable to owners -78,614-121,009
Balance Sheet
Item 201920202021-04
Cash and cash equivalents 41,428549,800
Trade and bills receivables 7,38610,359
Inventories 8,63818,423
Total current assets 195,549688,276
Total current liabilities 47,95348,757
Total equity 216,790728,517
Equity attributable to owners 216,790728,517
Interest-bearing borrowings 10,01200
Cash Flow Statement
Item 201920202021-04
Net cash from operating activities -17,954-9,575
Net cash from investing activities -95,141-1,222
Net cash from financing activities 100,876511,276
Net increase in cash -12,219500,479
Depreciation of PP&E 1,1063,2871,948
Depreciation of right-of-use assets 867493105
Amortisation of intangible assets 1,4571,704564
Purchase of PP&E -28,571-25,655-3,772
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 30.5
First Day OpenHK$ 31.0
First Day Change-73.97%
First Day Volume6776600.0
First Day Turnover207865000.0
Use of Proceeds
1、31%(或約562.7百萬港元)分配予我們的核心產品; 2、35%(或約635.3百萬港元)分配予我們的持續血糖監測系統; 3、11%(或約199.7百萬港元)將分配至我們第二代貼敷式胰島素泵系統的臨床 前研究、臨床試驗、注冊、生產及商業化; 4、8%(或約145.2百萬港元)將分配至我們其他產品及在研產品的臨床前研 究、臨床試驗、注冊、生產及商業化; 5、5%(或約90.8百萬港元)將用于為建立我們基于云端大數據的糖尿病管理平 臺提供資金; 6、10%(或約181.5百萬港元)將分配用于營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893
Joint Lead Managers (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Boyu Capital Opportunities Master Fund 77,832,950 HKD — 4.00% — 6 months 2022-04-19
2 Hudson Bay Master Fund LTD 97,288,900 HKD — 5.00% — 6 months 2022-04-19
3 Invesco Advisers, Inc. 272,413,800 HKD — 14.10% — 6 months 2022-04-19
4 Lake Bleu Prime Healthcare Master Fund Limited 77,832,950 HKD — 4.00% — 6 months 2022-04-19
5 LAV Star Limited 97,288,900 HKD — 5.00% — 6 months 2022-04-19
6 Octagon Investments Master Fund LP 77,832,950 HKD — 4.00% — 6 months 2022-04-19
7 OrbiMed Genesis Master Fund,L.P. 62,265,750 HKD — 3.20% — 6 months 2022-04-19
8 Sage Partners Master Fund 62,265,750 HKD — 3.20% — 6 months 2022-04-19
9 Springhill Master Fund Limited 97,288,900 HKD — 5.00% — 6 months 2022-04-19
10 Tencent Mobility Limited 77,832,950 HKD — 4.00% — 6 months 2022-04-19
11 UBS Asset Management (Singapore) Ltd. 194,580,850 HKD — 10.00% — 6 months 2022-04-19

Directors & Management

PositionChinese nameEnglish Name
Chairman鄭攀—
Company Secretary朵波、張夢弛—
No director data available.

Major Shareholders

Major Shareholders & Holdings鄭攀博士直接及通過杭州研泰、杭州衡泰控制本公司約34.17%已發行總股本(上市前為控股股東,上市後為單一最大股東集團);其他主要股東包括QM32 Limited(9.46%)、浙江九仁資本管理有限公司(7.79%)、施毅博士(7.12%)、江蘇疌泉醴澤健康產業創業投資基金(6.53%)等。
About this page

This page shows Microtech Med-B (02235) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect